Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients

被引：19

作者：

Ogihara, Toshio ^{[1
]}

Saruta, Takao ^{[2
]}

Rakugi, Hiromi ^{[1
]}

Shimamoto, Kazuaki ^{[3
]}

Ito, Sadayoshi ^{[4
]}

Matsuoka, Hiroaki ^{[5
]}

Horiuchi, Masatsugu ^{[6
]}

Imaizumi, Tsutomu ^{[7
]}

Takishita, Shuichi ^{[8
]}

Higaki, Jitsuo ^{[6
]}

Katayama, Shigehiro ^{[9
]}

Saito, Ikuo ^{[2
]}

Shimada, Kazuyuki ^{[10
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med & Nephrol, Suita, Osaka 5650871, Japan

[2] Keio Univ, Osaka, Japan

[3] Sapporo Med Univ, Sch Med, Osaka, Japan

[4] Tohoku Univ, Sch Med, Sendai, Japan

[5] Dokkyo Med Univ, Osaka, Japan

[6] Ehime Univ, Grad Sch Med, Osaka, Japan

[7] Kurume Univ, Sch Med, Osaka, Japan

[8] Univ Ryukyus, Sch Med, Osaka, Japan

[9] Saitama Med Univ, Osaka, Japan

[10] Jichi Med Univ, Osaka, Japan

来源：

HYPERTENSION RESEARCH | 2009年 / 32卷 / 02期

关键词：

clinical trial; combination therapy; olmesartan; BLOOD-PRESSURE; CARDIOVASCULAR EVENTS; TRIAL; AMLODIPINE; MEDOXOMIL; EFFICACY; OUTCOMES;

D O I：

10.1038/hr.2008.31

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

The COLM study is an investigator-initiated trial comparing the combination therapy using an angiotensin II receptor blocker (ARB), olmesartan, and a calcium channel blocker (CCB) with that using an ARB and a diuretic in high-risk elderly hypertensive patients. Here we describe the rationale and study design. Olmesartan was administered concomitantly with a long-acting dihydropyridine CCB (ARB/CCB group) or with a low-dose diuretic (ARB/diuretic group) to elderly hypertensive patients with a history of or risk factors for cardiovascular disease. Cardiovascular morbidity and mortality as a primary end point were compared between the two groups, with the target blood pressure (BP) being < 140 mm Hg for systolic BP and < 90 mm Hg for diastolic BR Safety and tolerability will also be investigated. A total of more than 4000 patients were recruited and will be followed up for at least 3 years.

引用

页码：163 / 167

页数：5

共 50 条

[41] Combination of Amlodipine plus Angiotensin Receptor Blocker or Diuretics in High-Risk Hypertensive PatientsA 96-Week Efficacy and Safety Study
Liyuan Ma
Wen Wang
Yong Zhao
Yuqing Zhang
Qing Deng
Mingbo Liu
Hui Sun
Jianchun Wang
Lisheng Liu
American Journal of Cardiovascular Drugs, 2012, 12 : 137 - 142
[42] Erratum to: Design and Rationale of Japanese Evaluation Between Formula of Azelnidipine and Amlodipine Add on Olmesartan to Get Antialbuminuric Effect Study (J-FLAG)Evaluation of the Antialbuminuric Effects between Calcium Channel Blocker with Sympatholytic Action in Hypertensive Patients with Diabetes and Albuminuria
Katsuyuki Ando
Masakazu Haneda
Sadayoshi Ito
Naoki Kashihara
Koichi Node
Masaomi Nangaku
Tatsuo Shimosawa
Junji Kishimoto
Toshiro Fujita
Cardiovascular Drugs and Therapy, 2011, 25 (4) : 365 - 366
[43] Management of high-risk hypertensive patients in Spain. The tarvest study
Barrios, V
Hernandez, R
Ruilope, LM
Redon, JM
De la Figuera, M
Calderon, A
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 140A - 140A
[44] COMBINATION OF AMLODIPINE WITH DIURETICS OR TELMISARTAN IN HIGH-RISK HYPERTENSIVE PATIENTS: THE CHINESE HYPERTENSION INTERVENTION EFFICACY STUDY (CHIEF)
Wang, Wen
Zhang, Yuqing
Ma, Liyuan
Lu, Peipei
Meng, Xu
Li, Yanqi
Wang, Shu
Zhang, Xuezhong
Ma, Lihong
Zhou, Xianliang
Liu, Lisheng
Hu, Aihua
JOURNAL OF HYPERTENSION, 2018, 36 : E260 - E260
[45] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic - The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Furberg, CD
Wright, JT
Davis, BR
Cutler, JA
Alderman, M
Black, H
Cushman, W
Grimm, R
Haywood, LJ
Leenen, F
Oparil, S
Probstfield, J
Whelton, P
Nwachuku, C
Gordon, D
Proschan, M
Einhorn, P
Ford, CE
Piller, LB
Dunn, JK
Goff, D
Pressel, S
Bettencourt, J
deLeon, B
Simpson, LM
Blanton, J
Geraci, T
Walsh, SM
Nelson, C
Rahman, M
Juratovac, A
Pospisil, R
Carroll, L
Sullivan, S
Russo, J
Barone, G
Christian, R
Feldman, S
Lucente, T
Calhoun, D
Jenkins, K
McDowell, P
Johnson, J
Kingry, C
Alzate, J
Margolis, KL
Holland-Klemme, LA
Jaeger, B
Williamson, J
Louis, G
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (23): : 2981 - 2997
[46] A TRI-CENTER STUDY ON THE EFFECTS OF THE CALCIUM-CHANNEL BLOCKER, NITRENDIPINE, ON LV MASS IN HYPERTENSIVE PATIENTS
HALL, WD
DRAYER, JIM
SMITH, VE
WEBER, MA
WOLLAM, G
WHITE, W
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (02) : 200 - 200
[47] Combination therapy of angiotensin II receptor blockers plus a calcium channel blocker, but not a diuretic, improve late systolic pressure augmentation in elderly patients with essential hypertension
Doi, M.
Miyoshi, T.
Hirohata, S.
Kusachi, S.
Kusano, K.
EUROPEAN HEART JOURNAL, 2009, 30 : 862 - 862
[48] A pilot study of bendamustine in elderly patients with high-risk MDS and AML
Strupp, C.
Knipp, S.
Hartmann, J.
Gattermann, N.
Haas, R.
Germing, U.
LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1161 - 1166
[49] Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk
Haller, H.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (05) : 781 - 790
[50] Adequacy of Blood Pressure Control in High-Risk Hypertensive Patients: The DEGREE Study
Zeijen, Victor
Lafeber, Melvin
Versmissen, Jorie
Kroon, Abraham
Boersma, Eric
Daemen, Joost
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (19) : B3 - B3

← 1 2 3 4 5 →